Fulcrum Therapeutics
FULC
38 hedge funds and large institutions have $262M invested in Fulcrum Therapeutics in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 4 closing their positions.
149% more capital invested
Capital invested by funds: $105M → $262M (+$157M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
0.52% less ownership
Funds ownership: 68.15% → 67.63% (-0.52%)
3% less funds holding
Funds holding: 39 → 38 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$3.78M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.99M |
| 3 |
BlackRock
New York
|
+$1.11M |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$610K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$553K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$3.38M |
| 2 |
Millennium Management
New York
|
-$2.11M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$1.79M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$714K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$585K |
FULC Hedge Fund Activity: Q4 2019 in Review
38 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q4 2019, worth a combined $262M — up 149% from $105M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FULC and 3 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 15 added.
The largest buyer was Casdin Capital, adding an estimated $3.78M. The largest seller was AllianceBernstein, exiting entirely with an estimated $3.38M sold.
- 38 institutional investors held Fulcrum Therapeutics (FULC) as of Q4 2019, down from 39 in Q3 2019.
- Funds reported $262M of Fulcrum Therapeutics stock for Q4 2019, up 149% quarter-over-quarter.
- 3 funds opened new Fulcrum Therapeutics positions in Q4 2019 and 4 closed out, a net change of -1 holder.
- The largest Fulcrum Therapeutics buyer in Q4 2019 was Casdin Capital, an estimated $3.78M added.
- The largest Fulcrum Therapeutics seller in Q4 2019 was AllianceBernstein, an estimated $3.38M sold.
Based on aggregated 13F filings for Q4 2019.